Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer

Abstract

Real-world evidence from clinical practices is fundamental for understanding the efficacy and tolerability of medicinal products. Patients with renal cell cancer were studied to gain data not represented by analyses conducted on highly selected patients participating in clinical trials. Our goal was to retrospectively collect data from patients with advanced renal tumours treated with pazopanib (PZ) to investigate the efficacy, frequency of side effects, and searching for predictive markers. Eighty-one patients who had received PZ therapy as first-line treatment were retrospectively evaluated. Overall survival (OS), progression-free survival (PFS) were assessed as endpoints. Median PFS and OS were 11.8 months (95% CI: 8.8-22.4); and 30.2 months (95% CI: 20.3-41.7) respectively. Severe side effects were only encountered in 11 (14%) patients. The presence of liver metastasis shortened the median PFS (5.5 vs. 14.8 months, p = 0.003). Median PFS for patients with or without side effects was 25.6 vs. 7.3 months, respectively (p = 0.0001). Patients younger than 65 years had a median OS of 41.7 months vs. 25.2 months for those over 65 years of age (p = 0.008). According to our results absence of liver metastases, younger age (<65 years) and presence of side effects proved to be independent predictive markers of better PFS and OS.

A case of pazopanib-induced acute kidney injury, reversible hair depigmentation and radiation recall dermatitis

“…However, the clinical efficacy of pazopanib is limited due to its association with adverse events (AEs), including kidney involvement [ 3 ]. Nevertheless, real-world evidence has shown that the presence of AEs is an independent predictive marker of better progress-free survival in mRCC [ 4 ]. Here, we describe a typical case of pazopanib-induced AEs, including acute kidney injury (AKI), hair depigmentation, and radiation recall dermatitis (RRD).…”